- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06761599
Frequency of Pulmonary Toxicity in Patients Treated for Hodgkin Lymphoma
January 5, 2025 updated by: Muhammad Naveed Babur, Superior University
Pulmonary toxicity during Hodgkin lymphoma treatment is significant for a variety of reasons, ranging from clinical care to therapeutic innovation and patient outcomes.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
Understanding chemotherapy-induced pulmonary issues, particularly bleomycin-induced toxicity, might enhance treatment efficacy, side effects, and quality of life for Hodgkin lymphoma patients.
For Hodgkin lymphoma chemotherapy patients with pulmonary difficulties, which result in significant patient morbidity and mortality, early detection, proactive surveillance, and rapid management are required.
Identifying the prevalence, risk factors, and clinical signs of pulmonary toxicity helps clinicians stratify treatment.
Study Type
Observational
Enrollment (Actual)
214
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Khyber Pakhtunkhwa
-
Peshawar, Khyber Pakhtunkhwa, Pakistan
- Shaukat Khanum Memorial Cancer Hospital and Research Centre, 5-B, Sector A2, Phase 5, Hayatabad
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Sampling Method
Probability Sample
Study Population
to check the Frequency of Pulmonary Toxicity in Patients Treated for Hodgkin Lymphoma
Description
Inclusion Criteria:
- Patients diagnosed with Hodgkin lymphoma (HL) receiving treatment.
- Patients of all ages and both genders.
- Patients with histologically confirmed HL, as per the WHO 2016 classification.
- Patients who have undergone pulmonary function testing and assessment at specified time points during their treatment course.
- Patients with complete medical records documenting treatment regimens, including chemotherapy and radiotherapy details.
Exclusion Criteria:
- Patients with a diagnosis of another malignancy.
- Patients with incomplete medical records or missing data on treatment regimens and pulmonary function assessments.
- Patients with a history of significant pulmonary comorbidities, such as chronic obstructive pulmonary disease (COPD), interstitial lung disease, or pulmonary fibrosis, before HL diagnosis.
- Patients who are unable to complete pulmonary function tests.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
high-resolution computed tomography
Time Frame: 12 Months
|
An HRCT (high-resolution computed tomography) scan is a type of CT scan healthcare providers use to get detailed images of your lungs.
Providers most commonly use it to diagnose and monitor interstitial lung diseases and conditions that affect your small airways and alveoli (air sacs).
|
12 Months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 18, 2024
Primary Completion (Actual)
July 15, 2024
Study Completion (Estimated)
March 1, 2025
Study Registration Dates
First Submitted
December 19, 2024
First Submitted That Met QC Criteria
January 5, 2025
First Posted (Actual)
March 25, 2025
Study Record Updates
Last Update Posted (Actual)
March 25, 2025
Last Update Submitted That Met QC Criteria
January 5, 2025
Last Verified
January 1, 2025
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MSAHS/Batch-Spring23/046
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.